A trend to improved performance during both the acquisition and testing phases was observed in rapamycin-treated non-transgenic animals, but these differences did not reach statistical significance.
← all excerpts
Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease.
1
—
—